New Zealand Opens Access to Clopidogrel, Leaving Out Sanofi's Plavix
This article was originally published in PharmAsia News
Executive Summary
TOKYO - New Zealand's Pharmaceutical Management Agency announced open access for cardiovascular drug clopidogrel, dropping patient price significantly, essentially removing Sanofi-Aventis' Plavix from the country's market